Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Wegovy (Semaglutide) FDA approval for chronic weight management in adults with obesity or overweight
Unlike SGLT2 inhibitors (another class of diabetes medication such as dapagliflozin or empagliflozin), which work by causing the kidneys to excrete excess glucose in urine and consequently increase urination, GLP-1 receptor agonists do not affect renal glucose handling or increase urinary glucose excretion
Your blood pressure will be monitored, and your doctor will guide you on what to look for and when to seek medical attention
We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises
US$ 26.76
US$ 21.16
US$ 26.21
US$ 26.89
